Abstract:ABSTRACT Clostridium species have gained attention in industrial and medical applications, and the development of genetic tools has enabled the advancement of the CRISPR-Cas systems for these bacteria. Compared to the primarily used Cas9 from Streptococcus pyogenes , the utilization of Cas12a (previously known as Cpf1) proteins remains incomplete in clostridia, although they exhibit potential advantages, including T-rich recognition for Clostridium genomes and lower toxicity. In this study, we expanded the CRISPR-Cas tools in clostridia by establishing a CRISPR-Cas12a system with two different cas12a genes ( Ascas12a from Acidaminococcus and Fncas12a from Francisella novicida ). The optimized tetracycline-inducible systems were initially determined by the glucuronidase reporter and were used to drive expression of the cas12a genes and crRNAs. Our results demonstrate that the CRISPR-FnCas12a system offers flexible target selection in clostridia, and a specific folding pattern of the precursor crRNA is important to enable high mutation generation efficiency. By using sacB (encoding levansucrase) as a negative marker for plasmid curing and determining the optimal size of the donor DNA template for gene integration in the CRISPR-FnCas12a system, we achieved highly efficient and rapid genome modification, exemplified by the successful engineering of clostridia ( Clostridium butyricum and Clostridium sporogenes ) to produce near-infrared fluorescence from biliverdin and hemin. IMPORTANCE Continued efforts in developing the CRISPR-Cas systems will further enhance our understanding and utilization of Clostridium species. This study demonstrates the development and application of a genome-engineering tool in two Clostridium strains, Clostridium butyricum and Clostridium sporogenes , which have promising potential as probiotics and oncolytic agents. Particular attention was given to the folding of precursor crRNA and the role of this process in off-target DNA cleavage by Cas12a. The results provide the guidelines necessary for efficient genome engineering using this system in clostridia. Our findings not only expand our fundamental understanding of genome-engineering tools in clostridia but also improve this technology to allow use of its full potential in a plethora of biotechnological applications.

Harnessing the endogenous Type I-C CRISPR-Cas system for genome editing in Bifidobacterium breve

Genomic and epigenetic landscapes drive CRISPR-based genome editing in Bifidobacterium

Characterization of CRISPR-Cas systems in Bifidobacterium breve

Exploiting heterologous and endogenous CRISPR‐Cas systems for genome editing in the probiotic Clostridium butyricum

Genome editing using the endogenous type I CRISPR-Cas system in Lactobacillus crispatus

[Optimization of CRISPR/Cas9-based multiplex base editing in Corynebacterium glutamicum].

Establishment of CRISPR-Cas9 system in Bifidobacteria animalis AR668

CRISPR/Cas-Based Genome Editing for Human Gut Commensal Bacteroides Species

Development of a CRISPR-Cas12a system for efficient genome engineering in clostridia

Application of different types of CRISPR/Cas-based systems in bacteria

High-Efficiency Genome Editing Based on Endogenous CRISPR-Cas System Enhances Cell Growth and Lactic Acid Production in Pediococcus acidilactici

Fine-Tuning Cas9 Activity with a Cognate Inhibitor AcrIIA4 to Improve Genome Editing in <i>Streptomyces</i>

A CRISPR-Cas-associated transposon system for genome editing in Burkholderia cepacia complex species

Design and Construction of Portable CRISPR-Cpf1-Mediated Genome Editing in Bacillus subtilis 168 Oriented Toward Multiple Utilities

Unleashing the potential: type I CRISPR-Cas systems in actinomycetes for genome editing

CRISPR-Cas-Based Engineering of Probiotics

Repurposing the Endogenous CRISPR-Cas9 System for High-Efficiency Genome Editing in Lacticaseibacillus paracasei

Harnessing the Native Type I-F CRISPR-Cas System of Acinetobacter baumannii for Genome Editing and Gene Repression

Using an Endogenous CRISPR-Cas System for Genome Editing in the Human Pathogen Clostridium difficile

Repurposing endogenous Type I-D CRISPR-Cas system for genome editing in Synechococcus sp. PCC7002

Prokaryotic genome editing based on the subtype I-B-Svi CRISPR-Cas system